It has been shown that in a clinical setting, the use of these inhibiting anti-CTLA-4 antibodies is able to enhance the activity of effector T cells while suppressing regulatory T cells, resulting in net inhibition of tumor progression [130]. Here, CTLA4 is linked to neoplasm.